Edwards Lifesciences Corp
EW
Market Cap$39.45B
Close$
Earnings Call Q2 2024
July 24, 2024 - AI Summary
Total company sales for Edwards Lifesciences in Q2 2024 increased by 8% on a constant currency basis compared to the previous year.
TAVR growth in Q2 was lower than expected, but the company remains confident in its differentiated technology and commitment to advancing evidence for AS patients.
The company announced two acquisitions: JenaValve, a pioneer in transcatheter treatment of aortic rehabilitation (AR), and Endotronix, a leader in heart failure management solutions. These acquisitions expand Edwards' portfolio into new therapeutic areas.
Exclusive for Stockcircle Pro members
Sign up
$45.73
30.2% downside
Current Fair Value
30.2% downsideOvervalued by 30.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $39.45 Billion |
|---|---|
| Enterprise Value | $38.43 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $2.31 |
| Beta | 1.13 |
| Outstanding Shares | 602,100,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 26.77 |
|---|---|
| PEG | 138.87 |
| Price to Sales | 7.28 |
| Price to Book Ratio | 5.46 |
| Enterprise Value to Revenue | 6.41 |
| Enterprise Value to EBIT | 23.79 |
| Enterprise Value to Net Income | 26 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.08 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Edwards Lifesciences Corp
CEO: Michael Mussallem